Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Local Institution
Little Rock, Arkansas, United States
Local Institution
Anaheim, California, United States
Local Institution
Cerritos, California, United States
Local Institution
Garden Grove, California, United States
Local Institution
National City, California, United States
Local Institution
San Diego, California, United States
Local Institution
New Britain, Connecticut, United States
Local Institution
North Miami, Florida, United States
Local Institution
Augusta, Georgia, United States
Local Institution
Macon, Georgia, United States
Start Date
March 1, 2004
Primary Completion Date
August 1, 2006
Completion Date
August 1, 2006
Last Updated
November 11, 2013
300
Estimated participants
Aripiprazole
DRUG
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions